Company Overview
Trinity Biotech plc operates within the Healthcare sector, specifically focusing on the Medical Devices industry, where it acquires, develops, manufactures, and markets medical diagnostic products for clinical laboratories and point-of-care segments across the Americas, Asia, Africa, and Europe. The company's business model centers on providing essential diagnostic solutions that support clinical decision-making in various global markets, positioning it as a specialized player in the broader healthcare infrastructure. As of the latest available data, Trinity Biotech plc holds a market capitalization of $11.36M and employs approximately 401 individuals to execute its operational and strategic initiatives. With annual revenue reported at $48.57M, the company presents a small-cap profile that suggests a niche market position rather than broad-scale dominance, indicating that its operations are likely concentrated in specific product lines or regional territories where it maintains a competitive foothold.
Financial Health
The company reported revenue of $48.57M over the trailing twelve months, yet this top-line activity resulted in a net income loss of $36,283,000, revealing a significant structural gap where operating expenses substantially exceed gross profits. EBITDA stands at $-14,029,000, further confirming that the business is currently burning cash before interest, taxes, depreciation, and amortization adjustments. Free cash flow is negative at $-7,285,750, which indicates that the company is consuming its cash reserves to fund operations and capital expenditures, thereby limiting its immediate financial flexibility to weather market downturns without additional financing. The gross margin sits at 36.8%, suggesting that the cost of goods sold consumes a majority of revenue, while the operating margin of -3.6% and profit margin of -75.9% highlight severe inefficiencies or high overhead costs relative to sales volume. The balance sheet shows a cash balance of $1.34M against total debt of $117.20M, creating a highly leveraged position where liabilities far outweigh liquid assets, and the debt-to-equity ratio is listed as N/A, implying that equity may be minimal or negative due to accumulated losses. The current ratio of 1.03 indicates that the company holds just enough current assets to cover current liabilities, placing short-term liquidity under tight scrutiny. Return on Equity is N/A, likely due to the lack of positive equity base, while the return on assets stands at -9.5%, revealing that management is currently destroying value relative to the asset base employed in the business.
Valuation Assessment
The P/E Ratio (TTM) is N/A because the company is not currently profitable, while the forward P/E is -0.58, a negative figure that reflects the market's pricing of future expectations against a backdrop of current losses rather than established earnings power. The price-to-book ratio is -0.20, a metric that typically appears when book value is negative or negligible, suggesting that the market price does not reflect a traditional premium over tangible assets but rather prices in significant intangible value or distressed conditions. The price-to-sales ratio is 0.23, and the EV/EBITDA is -24.24, both of which serve as alternative valuation metrics that suggest the stock is priced low relative to sales but remain distorted by negative earnings multiples. The 52-week high is $3.44 and the 52-week low is $0.48, meaning the current market price sits within a wide trading band that reflects extreme volatility and uncertainty regarding the company's future trajectory. The beta is 0.70, indicating that the stock's price volatility is lower than the broader market, suggesting that Trinity Biotech plc may be less sensitive to general market swings than large-cap peers, though this low beta can also signal lower liquidity or a lack of institutional interest.
Growth & Income
Revenue growth year-over-year is -5.5%, and earnings growth year-over-year is N/A due to the absence of recent profitability, implying that the company is currently in a contraction phase regarding top-line sales rather than an expansion phase. The company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning that any generated earnings are theoretically available for reinvestment, though currently, the firm is utilizing cash reserves to sustain operations. Since the firm does not distribute cash to shareholders, the implicit strategy relies on retaining capital to fund R&D or acquisition activities, although the current negative free cash flow restricts the ability to aggressively reinvest without external capital injection. The overall growth and income profile is characterized by a lack of positive earnings growth, zero dividend income, and a declining revenue trend, which collectively paint a picture of a business unit facing significant headwinds in its current market environment.